Mark J. Anderton

2.4k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Mark J. Anderton is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark J. Anderton has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark J. Anderton's work include Bioactive Compounds and Antitumor Agents (2 papers), Advanced Breast Cancer Therapies (2 papers) and Synthesis of Indole Derivatives (2 papers). Mark J. Anderton is often cited by papers focused on Bioactive Compounds and Antitumor Agents (2 papers), Advanced Breast Cancer Therapies (2 papers) and Synthesis of Indole Derivatives (2 papers). Mark J. Anderton collaborates with scholars based in United Kingdom, United States and Sweden. Mark J. Anderton's co-authors include John Garthwaite, Eric Southam, Margaret M. Manson, Marion L. Williams, William P. Steward, Andreas J. Gescher, Richard D. Verschoyle, John H. Lamb, Howard R. Mellor and Steve Powell and has published in prestigious journals such as Nature Reviews Drug Discovery, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mark J. Anderton

14 papers receiving 1.1k citations

Hit Papers

Impact of a five-dimensional framework on R&D product... 2018 2026 2020 2023 2018 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Impact of a five-dimensional framework on R&D productivity at AstraZeneca
    2018 271 citations Paul Morgan, Dean G. Brown et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark J. Anderton United Kingdom 9 558 170 160 141 140 14 1.1k
Yves Jacquot France 22 711 1.3× 177 1.0× 146 0.9× 72 0.5× 226 1.6× 61 1.3k
Doriano Fabbro United States 12 900 1.6× 142 0.8× 179 1.1× 190 1.3× 62 0.4× 14 1.5k
Lisa A. Paige United States 10 1.0k 1.9× 93 0.5× 228 1.4× 223 1.6× 92 0.7× 13 1.6k
Shangli Zhang China 20 690 1.2× 98 0.6× 113 0.7× 79 0.6× 122 0.9× 65 1.5k
Irina N. Gaisina United States 23 931 1.7× 270 1.6× 135 0.8× 211 1.5× 210 1.5× 59 1.6k
Kim Masuda United States 15 621 1.1× 121 0.7× 127 0.8× 237 1.7× 133 0.9× 17 1.4k
Karima Bettayeb France 18 731 1.3× 296 1.7× 316 2.0× 101 0.7× 397 2.8× 21 1.5k
Jen‐Shin Song Taiwan 22 625 1.1× 91 0.5× 273 1.7× 132 0.9× 346 2.5× 58 1.4k
Elisabetta Barresi Italy 24 649 1.2× 114 0.7× 315 2.0× 143 1.0× 472 3.4× 77 1.4k
Simon Frantz United States 12 497 0.9× 97 0.6× 113 0.7× 59 0.4× 137 1.0× 67 921

Countries citing papers authored by Mark J. Anderton

Since Specialization
Citations

This map shows the geographic impact of Mark J. Anderton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Anderton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Anderton more than expected).

Fields of papers citing papers by Mark J. Anderton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Anderton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Anderton. The network helps show where Mark J. Anderton may publish in the future.

Co-authorship network of co-authors of Mark J. Anderton

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Anderton. A scholar is included among the top collaborators of Mark J. Anderton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Anderton. Mark J. Anderton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Wallez, Yann, Theresa A. Proia, Ankur Karmokar, et al.. (2022). Abstract 5298: Activity and tolerability of combinations of trastuzumab deruxtecan (T-DXd) with inhibitors of the DNA damage response in preclinical models. Cancer Research. 82(12_Supplement). 5298–5298. 1 indexed citations
2.
Gill, Sonja J., Ruth S. MacDonald, Carmen Pin, et al.. (2021). Abstract 1374: The novel PARP1-selective inhibitor AZD5305 has reduced hematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models. Cancer Research. 81(13_Supplement). 1374–1374. 2 indexed citations
3.
Morgan, Paul, Dean G. Brown, Simon Lennard, et al.. (2018). Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery. 17(3). 167–181. 271 indexed citations breakdown →
4.
Bojang, Pasano, Mark J. Anderton, Ruth Roberts, & Kenneth S. Ramos. (2014). De novo LINE - 1 retrotransposition in HepG2 cells preferentially targets gene poor regions of chromosome 13. Genomics. 104(2). 96–104. 5 indexed citations
5.
Anderton, Mark J., et al.. (2014). Abstract 3676: Influence of early toxicology assessment on the selection of azd9291. Cancer Research. 74(19_Supplement). 3676–3676. 1 indexed citations
6.
Bojang, Pasano, Ruth Roberts, Mark J. Anderton, & Kenneth S. Ramos. (2013). Reprogramming of the HepG2 genome by long interspersed nuclear element‐1. Molecular Oncology. 7(4). 812–825. 18 indexed citations
7.
8.
Priestley, Catherine, Mark J. Anderton, Ann Doherty, et al.. (2012). Epigenetics – relevance to drug safety science. Toxicology Research. 1(1). 23–31. 8 indexed citations
9.
Anderton, Mark J., Howard R. Mellor, Alex Bell, et al.. (2011). Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors. Toxicologic Pathology. 39(6). 916–924. 211 indexed citations
10.
Anderton, Mark J., Margaret M. Manson, Richard D. Verschoyle, et al.. (2004). PHYSIOLOGICAL MODELING OF FORMULATED AND CRYSTALLINE 3,3′-DIINDOLYLMETHANE PHARMACOKINETICS FOLLOWING ORAL ADMINISTRATION IN MICE. Drug Metabolism and Disposition. 32(6). 632–638. 106 indexed citations
11.
Anderton, Mark J., Margaret M. Manson, Richard D. Verschoyle, et al.. (2004). Pharmacokinetics and Tissue Disposition of Indole-3-carbinol and Its Acid Condensation Products after Oral Administration to Mice. Clinical Cancer Research. 10(15). 5233–5241. 185 indexed citations
12.
Anderton, Mark J., Rebekah Jukes, John H. Lamb, et al.. (2003). Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. Journal of Chromatography B. 787(2). 281–291. 45 indexed citations
13.
14.
Garthwaite, John, Eric Southam, & Mark J. Anderton. (1989). A Kainate Receptor Linked to Nitric Oxide Synthesis from Arginine. Journal of Neurochemistry. 53(6). 1952–1954. 186 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yves Jacquot Breakdown of academic impact, for papers by Doriano Fabbro Breakdown of academic impact, for papers by Lisa A. Paige Breakdown of academic impact, for papers by Shangli Zhang Breakdown of academic impact, for papers by Irina N. Gaisina Breakdown of academic impact, for papers by Kim Masuda Breakdown of academic impact, for papers by Karima Bettayeb Breakdown of academic impact, for papers by Jen‐Shin Song Breakdown of academic impact, for papers by Elisabetta Barresi Breakdown of academic impact, for papers by Simon Frantz
Rankless by CCL
2026